MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Personal Cancer Immunotherapy
    • The Clean Super Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Personal Cancer Immunotherapy
    • The Clean Super Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
  •  
  • Uncategorized

AIVITA Biomedical Appoints Chief Financial Officer and Vice President of Business Development

AIVITA Biomedical Announces Initiation of First Clinical Site for ROOT OF CANCER Glioblastoma Trial

AIVITA Biomedical to Speak and Exhibit Skincare Products at August Aesthetics Conferences

AIVITA Biomedical Receives $1.7 million in Funding as Part of UCI Awarded CIRM Grant to Treat Vision Loss

AIVITA Biomedical Announces U.S. Food and Drug Administration Clearance of IND for Phase II Glioblastoma Multiforme Trial

AIVITA Biomedical Randomizes First Patient in Phase II Ovarian Cancer Trial

AIVITA Biomedical Raises $15M USD in Series B Financing

AIVITA Biomedical to Exhibit Skincare Products at Upcoming Conferences for Aesthetic and Skincare Medical Professionals

AIVITA Biomedical CEO Hans Keirstead to Deliver Plenary Keynote at GTCbio’s 15th Stem Cell Summit

AIVITA Biomedical Scientists Invited to Deliver Keynote Address at HAPPI Anti-Aging Conference

  • Previous
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next

AIVITA Biomedical is a biotechnology company developing personalized vaccines that target infectious diseases and tumor-initiating cells — the seed of all cancers — using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

Recent News

  • AIVITA Biomedical Strengthens Board of Directors with Appointment of Global Health and Vaccine Readiness Leader Larry Brilliant
  • AIVITA Biomedical Nominated for 2026 Prix Galien USA Award
  • AIVITA Biomedical Licenses Novel Skincare Formulations to Global Skincare Retailer LevEllis
  • AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Join Keynote Panel for AI in Public Health at World Vaccine Congress

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2023 | AIVITA Biomedical, Inc.